No takes yet. Share an insight, caveat, or question.
Review uncovers widespread epigenetic reprogramming driving tumorigenesis across malignancies, highlighting reversible modifications as viable targets for novel cancer therapies.
Sharma et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: